Latest news with #TempusAI
Business Wire
16 hours ago
- Business
- Business Wire
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the 'Class Period'), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc. Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Tempus AI class action lawsuit, please provide your information here: CASE ALLEGATIONS: Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI. The Tempus AI class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (ii) the credibility and substance of Tempus AI's joint venture with SoftBank Group Corporation was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus AI; (iii) Tempus AI-acquired Ambry Genetics Corporation had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (iv) AstraZeneca PLC had reduced its financial commitments to Tempus AI through a questionable 'pass-through payment' via a joint agreement between it, Tempus AI, and Pathos AI, Inc.; and (v) the above issues revealed weakness in core operations and revenue prospects. The Tempus AI class action lawsuit further alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued research report on Tempus AI that raised numerous red flags over Tempus AI's management, operations, and financial reporting. On this news, the price of Tempus AI stock fell more than 19%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Tempus AI common stock during the Class Period to seek appointment as lead plaintiff in the Tempus AI class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Tempus AI class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Tempus AI class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Tempus AI class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Yahoo
7 days ago
- Business
- Yahoo
Tempus AI (NasdaqGS:TEM) Soars 51% In Last Quarter
In an exciting development for Tempus AI, the company experienced a significant 51% increase in its share price over the last quarter. This surge coincides with major events including their collaboration with The Abrams Research Center to advance Alzheimer's research and a partnership with Verastem Oncology for ovarian cancer diagnostics. Additionally, the introduction of innovative products like the liquid biopsy assay for treatment response monitoring reflects Tempus AI's active expansion in AI and precision medicine. With a broad market showing an 11% rise over the past year, Tempus AI's performance is notably robust amidst industry-wide growth projections. We've discovered 3 possible red flags for Tempus AI that you should be aware of before investing here. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 24 best rare earth metal stocks of the very few that mine this essential strategic resource. Tempus AI's shares demonstrated impressive resilience, achieving a substantial 77.09% total return over the past year. This outpaced both the broader U.S. market, which returned 10.6%, and the life sciences industry, which saw a decline of 23.1%. The robust share performance aligns with several strategic alliances and innovative product launches over the last year, potentially enhancing Tempus AI's revenue streams in precision medicine and AI-driven diagnostics. Despite strong revenue forecasts with expected annual growth of 21.71%, Tempus AI faces challenges with its profitability, recording a loss of US$68.04 million in the first quarter of 2025. The significant share price increase, however, positions the company above the consensus analyst price target of US$65.50. While the developments may bolster revenue, the market's valuation of Tempus AI highlights a discrepancy given its current unprofitability and Price-To-Sales Ratio of 15.4x compared to the industry average. The next quarters will be crucial in determining whether the company's strategic initiatives translate into a sustainable financial turnaround. Examine Tempus AI's past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:TEM. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Business
- Yahoo
Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach
ForTempus AI TEM, expanding partnerships with existing customers across each of its product lines is key to its growth. In April 2025, the AI-driven precision medicine company extended its collaboration with its earliest strategic client, AstraZeneca AZN. It teamed up with biotech company Pathos Inc. on a three-year, $200 million data and modeling license agreement. The three-way deal will build the largest multimodal foundation model in oncology, leveraging more than 300 petabytes of rich multimodal healthcare data that Tempus has built over the past decade. Notably, the deal raised the total remaining contract value to greater than $1 billion as of AstraZeneca, the partnership builds on its data and AI-driven R&D strategy, with the foundational model expected to speed up and increase the chances of clinical success across its broad pipeline. Meanwhile, Pathos is tapping into the growing trend of AI in drug discovery and development with this deal. Also in April, Tempus AI expanded its partnership with Illumina ILMN to help make molecular profiling part of the standard of care across more disease areas, including cardiology, neurology and immunology. Both Illumina and Tempus have a long-shared history of addressing gaps in testing, from pre-emptive screening and therapy selection to health economics and bioinformatics pipelines. Since molecular profiling is not yet standard across many disease areas and regions, patients often miss out on the benefits of precision medicine. Under this agreement, Tempus' multimodal data will enhance Illumina's AI-driven molecular analysis technologies, generating new insights that support the clinical value of sequencing. These will help create evidence packages needed to standardize the use of comprehensive genomic profiling and other molecular testing beyond cancer. The company also extended its commercial relationship with Personalis PSNL in December last year. After a strong response in the diagnostic market, Tempus now offers Personalis' NeXT Personal minimal residual disease (MRD) product to pharmaceutical and biotech customers. The strategic step allows Personalis to broaden market access of its ultra-sensitive MRD platform and leverage Tempus' integrated platform to serve biopharma customers who seek to bundle MRD testing with other Tempus products. Over the past year, Tempus AI shares have surged 77% compared with the industry's 39.7% growth. Image Source: Zacks Investment Research Tempus AI has a stretched valuation, with shares trading at a forward five-year Price-to-Sales (P/S) of 8.85X compared to the industry average of 6.34X. It carries a Value Score of F. Image Source: Zacks Investment Research Take a look at how the Zacks Consensus Estimate for Tempus AI's earnings has been revised over the past 90 days. Image Source: Zacks Investment Research TEM stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report Personalis, Inc. (PSNL) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Associated Press
14-06-2025
- Business
- Associated Press
TEMPUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to Contact the Firm
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tempus AI, Inc. ('Tempus' or the 'Company') (NASDAQ: TEM) in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Tempus securities between August 6, 2024 and May 27, 2025, both dates inclusive (the 'Class Period'). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025. If you purchased or otherwise acquired Tempus shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 [email protected]
Yahoo
13-06-2025
- Business
- Yahoo
Veteran analyst unveils bold price target for Tempus AI stock
Veteran analyst unveils bold price target for Tempus AI stock originally appeared on TheStreet. While much of Wall Street is focused on AI chipmakers and cloud giants, one AI health care stock is quietly making big moves. Tempus AI () , founded in 2015, uses artificial intelligence to help physicians make personalized, data-driven decisions. The stock, which went public in June 2024, has surged 12% over the past five days and 109% this year, even after a sharp drop in late May triggered by a short-seller report questioning its business model. The stock plunged more than 19% on May 28 after short-seller Spruce Point Capital Management released a report raising concerns about management's alleged history of promoting disruptive technology companies with revenue recognition issues and shareholder losses. The report also questioned the validity of Tempus AI's artificial intelligence services, citing minimal revenues and product demonstrations. Tempus AI responded that the report was "riddled with hypotheticals and inaccuracies and fails to address Tempus' history of strong financial performance and impressive growth." In its most recent earnings report released on May 6, the company posted 75.4% revenue growth year-over-year and raised its full-year forecast to $1.25 billion, reflecting roughly 80% growth from the previous year. However, the company is still not profitable, and net loss for the quarter widened to $68 million from $64.7 million. Ark Invest founder and CEO Cathie Wood is one of Tempus AI's most high-profile backers. She has been actively buying Tempus AI's stock since last June's IPO. Most recently, her funds purchased 251,080 shares of Tempus AI on May 28, a stake valued at roughly $17.8 million of June 11, Tempus AI is the sixth-largest holding in the flagship Ark Innovation ETF () , making up 5.8% of the fund's portfolio with a market value of $364.6 million. 'We've got 37 trillion cells in our body, and they're going to be sequenced as we're looking for cures,' Wood said in a February CNBC interview. 'I think the most underappreciated application of AI is health care. I think health care is responsible for an incredible amount of storage out there right now. Data is the name of the game.' In response to the earlier short report, Ark's team said it investigated the allegations and remains confident in the company's mission and technology. Tempus has also caught the attention of former House Speaker Nancy Pelosi, who earlier this year bought 50 call options on the stock (a bet that it would rise) valued at least $50,000. Barchetta Capital Management Managing Director Ed Ponsi is also bullish on Tempus AI. In a memo published at TheStreet Pro, Ponsi highlighted both the company's market potential and technical setup. 'This AI stock could be at the forefront of a medical revolution,' Ponsi wrote. 'AI will disrupt the medical industry via its ability to analyze vast amounts of information in seconds. It will speed the development of new drugs and therapies, streamline the drug manufacturing process and interact with patients.'Ponsi pointed to a series of rounded bottoms on the stock's chart (a bullish pattern) and identified $70 as a key resistance level. That threshold has now been cleared as Tempus AI closed at $70.78 on June 11. More Tech Stocks: Palantir gets great news from the Pentagon Analyst has blunt words on Trump's iPhone tariff plans OpenAI teams up with legendary Apple exec "Because Tempus AI fell quickly and sharply from that high in February, no subsequent support or resistance levels were created between the current price and the all-time high. This means a move to the $90 area or higher could happen quickly," Ponsi noted. Ponsi's price target for Tempus AI stock is $ analyst unveils bold price target for Tempus AI stock first appeared on TheStreet on Jun 12, 2025 This story was originally reported by TheStreet on Jun 12, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
